[{"id":"613e6d83-8a24-4773-9fa7-ac0078156fbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02131753","created_at":"2021-01-18T09:53:21.117Z","updated_at":"2024-07-02T16:35:48.422Z","phase":"Phase 2/3","brief_title":"Therapy Optimisation for the Treatment of Hairy Cell Leukemia","source_id_and_acronym":"NCT02131753","lead_sponsor":"University of Giessen","biomarkers":" CD19 • IL2RA • ITGAE • ISG20","pipe":"","alterations":" ","tags":["CD19 • IL2RA • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-10"},{"id":"55b7a154-a1a8-4a84-8f77-68505d4bda6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05330377","created_at":"2022-04-15T12:53:52.419Z","updated_at":"2025-02-25T15:27:20.156Z","phase":"Phase 1","brief_title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","source_id_and_acronym":"NCT05330377","lead_sponsor":"Ayman H Qasrawi","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • mitoxantrone • cladribine • Neupogen (filgrastim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 05/30/2027","primary_completion_date":" 05/30/2027","study_txt":" Completion: 05/30/2032","study_completion_date":" 05/30/2032","last_update_posted":"2023-04-25"}]